Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00119678
Registration number
NCT00119678
Ethics application status
Date submitted
30/06/2005
Date registered
14/07/2005
Date last updated
22/09/2014
Titles & IDs
Public title
Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
Query!
Scientific title
A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept vs Placebo on a Background of Oral Glucocorticosteroids in the Treatment of Subjects With Systemic Lupus Erythematosus and the Prevention of Subsequent Lupus Flares
Query!
Secondary ID [1]
0
0
IM101-042
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Abatacept
Treatment: Drugs - Placebo
Treatment: Drugs - Prednisone
Treatment: Drugs - Abatacept
Active comparator: Abatacept + Prednisone - Double Blind Period
Placebo comparator: Placebo + Prednisone - Double Blind Period
Experimental: Abatacept - Open Label
Treatment: Drugs: Abatacept
Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
Treatment: Drugs: Placebo
Injectable, intravenous, 0 mg, every 28 days, 12 months
Treatment: Drugs: Prednisone
Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
Treatment: Drugs: Abatacept
Injectable, intravenous, 10 mg/kg, every 28 days
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare
Query!
Assessment method [1]
0
0
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved. Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
Query!
Timepoint [1]
0
0
From start of corticosteroid taper to Day 365
Query!
Primary outcome [2]
0
0
Open Label Period (OL); Number of Participants Who Died, Experienced Adverse Events (AEs), Serious AEs, Drug Related AEs or SAEs and Discontinued Due to AEs
Query!
Assessment method [2]
0
0
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to an AE were recorded. Drug-related AEs or SAEs: events with a relationship to the study therapy of certain; probable; possible; or missing.
Query!
Timepoint [2]
0
0
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Query!
Primary outcome [3]
0
0
OL; Number of Participants With Significant AEs of Special Interest
Query!
Assessment method [3]
0
0
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs of particular importance were associated with the use of immunomodulatory agents. Number of participants with infections, malignant Neoplasms, pre-specified autoimmune disorders, acute-infusional AEs and peri-infusional AEs were recorded.
Query!
Timepoint [3]
0
0
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Query!
Primary outcome [4]
0
0
OL; Number of Participants With Marked Abnormalities (MAs) in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count
Query!
Assessment method [4]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* lower limit of normal (LLN) or \>1.5\* upper limit of normal (ULN) (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).
Query!
Timepoint [4]
0
0
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Query!
Primary outcome [5]
0
0
OL; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
Query!
Assessment method [5]
0
0
MMAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.
Query!
Timepoint [5]
0
0
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Query!
Primary outcome [6]
0
0
OL; Number of Participants With MAs in Serum Chemistry: Alkaline Phosphatase (ALP), Aspartate-aminotransferase (AST), Alanine-aminotransferase (ALT), Gamma-glutamyl Transferase (GGT), Bilirubin(Total), Blood Urea Nitrogen (BUN), Creatinine
Query!
Assessment method [6]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.
Query!
Timepoint [6]
0
0
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Query!
Primary outcome [7]
0
0
OL; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total), Protein (Total)
Query!
Assessment method [7]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95x LLN or \>1.05x ULN (if pre-Rx\<LLN, then \<0.95x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05x pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9x LLN or \>1.1xULN (if pre-Rx \<LLN, then \<0.9xpre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1xpre-Rx or \<LLN; Calcium (total): \<0.8xLLN or \>1.2xULN (if pre-Rx \<LLN, then \<0.75x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25x pre-Rx or \<LLN.
Query!
Timepoint [7]
0
0
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Query!
Primary outcome [8]
0
0
OL; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides
Query!
Assessment method [8]
0
0
MAs are laboratory measurements marked as abnormal, as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.
Query!
Timepoint [8]
0
0
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Query!
Primary outcome [9]
0
0
OL; Number of Participants With MAs in Urinalysis
Query!
Assessment method [9]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, red blood cells (RBC), white blood cells (WBC): \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; Glomerular filtration rate (GFR): \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.
Query!
Timepoint [9]
0
0
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Query!
Secondary outcome [1]
0
0
DB; Number of Participants With a New SLE Flare During the Initial 6 Months
Query!
Assessment method [1]
0
0
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
Query!
Timepoint [1]
0
0
From start of corticosteroid taper to 6 months.
Query!
Secondary outcome [2]
0
0
DB; Total Number of New SLE Flares Each Participant Experienced
Query!
Assessment method [2]
0
0
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
Query!
Timepoint [2]
0
0
From start of corticosteroid taper to Day 365
Query!
Secondary outcome [3]
0
0
DB; Median Number of Days to the First Occurrence of a New SLE Flare
Query!
Assessment method [3]
0
0
Elapsed days between start of corticosteroid taper \& first day of flare.Scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of corticosteroid taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
Query!
Timepoint [3]
0
0
From start of corticosteroid taper to confirmation of disease flare or the end of double-blind period
Query!
Secondary outcome [4]
0
0
DB; Number of Participants With a Change in the SLICC/ACR Damage Index at 1 Year Compared to Baseline
Query!
Assessment method [4]
0
0
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as non-reversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as =1. The total maximum score is 48, and increasing score indicates increasing disease severity.
Query!
Timepoint [4]
0
0
From start of study drug treatment to Day 365
Query!
Secondary outcome [5]
0
0
DB; Number of Participants Who Died, Experienced AEs, Other SAEs or Discontinuations Due to AEs, Drug Related AEs
Query!
Assessment method [5]
0
0
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs: events with a certain; probable; possible; or missing relationship to the study therapy. Participants who discontinued the study due to an AE were recorded.
Query!
Timepoint [5]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [6]
0
0
DB; Number of Participants With Significant AEs of Special Interest
Query!
Assessment method [6]
0
0
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of special interest were associated with the use of immunomodulatory agents. Number of participants with infections, malignant neoplasms, pre-specified autoimmune disorders, acute infusional AEs and peri-infusional AEs were recorded.
Query!
Timepoint [6]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [7]
0
0
DB; Number of Participants With MAs in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count
Query!
Assessment method [7]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* LLN or \>1.5\* ULN (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).
Query!
Timepoint [7]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [8]
0
0
DB; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
Query!
Assessment method [8]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.
Query!
Timepoint [8]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [9]
0
0
DB: Number of Participants With MAs in Serum Chemistry: ALP, AST, ALT, GGT, Bilirubin (Total), BUN and Creatinine
Query!
Assessment method [9]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.
Query!
Timepoint [9]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [10]
0
0
DB; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total),Protein (Total)
Query!
Assessment method [10]
0
0
MAs are laboratory measurements marked as abnormal as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95\* LLN or \>1.05\* ULN (if pre-Rx \<LLN, then \<0.95\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05\* pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9\* LLN or \>1.1\* ULN (if pre-Rx \<LLN, then \<0.9\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1\* pre-Rx or \<LLN; Calcium (total): \<0.8\* LLN or \>1.2\* ULN (if pre-Rx \<LLN, then \<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25\* pre-Rx or \<LLN.
Query!
Timepoint [10]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [11]
0
0
DB; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides
Query!
Assessment method [11]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dl or \>220 mg/dl; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.
Query!
Timepoint [11]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [12]
0
0
DB; Number of Participants With MAs in Urinalysis
Query!
Assessment method [12]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, RBC, WBC: \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* pre-Rx, or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; GFR: \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.
Query!
Timepoint [12]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [13]
0
0
DB; Number of Participants With Clinically Significant Abnormal Vital Signs and/or Physical Examination Findings
Query!
Assessment method [13]
0
0
Vital signs assessments and physical examination were conducted throughout the study. Vital signs assessments included body temperature, respiratory rate, blood pressure (systolic and diastolic) and heart rate. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs or physical examination were clinically meaningful.
Query!
Timepoint [13]
0
0
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Query!
Secondary outcome [14]
0
0
DB; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment
Query!
Assessment method [14]
0
0
Electrochemiluminescence (ECL) immunoassay based on Meso Scale Discovery (MSD) technology was used to detect antibodies specific for CTLA4-T and for abatacept.
Query!
Timepoint [14]
0
0
From Day 1 to Day 365
Query!
Secondary outcome [15]
0
0
OL; Number of Participants With a New SLE Flare
Query!
Assessment method [15]
0
0
SLE flares scored using BILAG:A:presence of =\>1 serious lupus features;B:more moderate features;C:mild symptomatic features;D:prior activity with no current symptoms due to active lupus;E:an organ that has never been involved.BILAG scores based on degrees of change in clinical features (1=improving,2=staying the same,3=worsening,4=new).New SLE flare means new BILAG A/B features in any organ system.Based on the recommendation of the Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
Query!
Timepoint [15]
0
0
From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.
Query!
Secondary outcome [16]
0
0
OL; Number of Participants With a Change in the SLICC/ACR Damage Index at Year 2 Compared to Baseline
Query!
Assessment method [16]
0
0
SLICC/ACR damage index:measure of cumulative damage due to SLE.Damage=non-reversible change occurring since onset of lupus,ascertained by clinical assessment \& present for =\>6 months.Scores of SLICC/ACR index:1:single episode;2:repeated episodes at least 6 months apart.Change in score from baseline to 1 year presented as:no change,increase 1 (an increase in score of 1),increase \>1 (an increase in score of \>1).Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
Query!
Timepoint [16]
0
0
From start of study drug therapy in open-label period (Day 365) and on Day 729.
Query!
Secondary outcome [17]
0
0
OL; Total Number of BILAG A Flares Each Participant Experienced
Query!
Assessment method [17]
0
0
Total number of BILAG A flares in any organ system after steroid tapering = new BILAG A features in any organ system. Scores defined as follows: None: participants with no BILAG A flare; 1: participants with 1 BILAG A flare or participants who discontinued without a new BILAG A flare were imputed as having one event. 2: participants with 2 BILAG A flares; 3 or \>3: participants with 3 or more BILAG A flares.Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
Query!
Timepoint [17]
0
0
From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.
Query!
Secondary outcome [18]
0
0
OL; Area Under the Curve (AUC) for Prednisone or Prednisone Equivalent
Query!
Assessment method [18]
0
0
Total exposure to glucocorticosteroid was measured by the total prednisone or prednisone equivalent AUC. Based on the recommendation of the Data Monitoring Committee, the open-label, long-term extension period was terminated by the sponsor, for failure to meet the primary outcome measure for the double-blind period and because of an increase in SAEs in the abatacept treatment group. As such, these data were not analyzed.
Query!
Timepoint [18]
0
0
From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.
Query!
Secondary outcome [19]
0
0
OL; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment
Query!
Assessment method [19]
0
0
MSD technology was used to detect antibodies specific for CTLA4-T and for abatacept.
Query!
Timepoint [19]
0
0
After the first dose of open-label period
Query!
Eligibility
Key inclusion criteria
* participants must be diagnosed with SLE and be experiencing an active lupus flare in at least one of three organ systems: skin (discoid lesions), inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints within 14 days of a screening visit (arthritis)
* Stable dose of prednisone (<30mg) for at least one month
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* participants experiencing an active lupus flare in the kidney or central nervous systems
* Treatment with a stable dose of azathioprine, mycophenolate mofetil, hydroxychloroquine, chloroquine, or methotrexate for less than three months prior to the study
* participants with active viral or bacterial infections
* participants with any other autoimmune disease as a main diagnosis
* Prior treatment with rituximab
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
183
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - Cairns
Query!
Recruitment hospital [2]
0
0
Local Institution - Maroochydore
Query!
Recruitment hospital [3]
0
0
Local Institution - Clayton
Query!
Recruitment hospital [4]
0
0
Local Institution - Heidelberg
Query!
Recruitment hospital [5]
0
0
Local Institution - Malvern
Query!
Recruitment postcode(s) [1]
0
0
4870 - Cairns
Query!
Recruitment postcode(s) [2]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
3144 - Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nevada
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oklahoma
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Graz
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Bruxelles
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Leuven
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
Goias
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
Parana
Query!
Country [16]
0
0
Brazil
Query!
State/province [16]
0
0
Rio De Janeiro
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
Sao Paulo
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
British Columbia
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Manitoba
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Bordeaux Cedex
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Montpellier Cedex 5
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Paris Cedex 14
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Berlin
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Duesseldorf
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Freiburg
Query!
Country [26]
0
0
Italy
Query!
State/province [26]
0
0
Ferrara
Query!
Country [27]
0
0
Korea, Republic of
Query!
State/province [27]
0
0
Sungdong-Gu
Query!
Country [28]
0
0
Korea, Republic of
Query!
State/province [28]
0
0
Seoul
Query!
Country [29]
0
0
Mexico
Query!
State/province [29]
0
0
Distrito Federal
Query!
Country [30]
0
0
Mexico
Query!
State/province [30]
0
0
Michioacan
Query!
Country [31]
0
0
Mexico
Query!
State/province [31]
0
0
Aguascalientes
Query!
Country [32]
0
0
Puerto Rico
Query!
State/province [32]
0
0
Ponce
Query!
Country [33]
0
0
South Africa
Query!
State/province [33]
0
0
Kwa Zulu Natal
Query!
Country [34]
0
0
South Africa
Query!
State/province [34]
0
0
Western Cape
Query!
Country [35]
0
0
Taiwan
Query!
State/province [35]
0
0
Kaohsiung
Query!
Country [36]
0
0
Taiwan
Query!
State/province [36]
0
0
Taichung
Query!
Country [37]
0
0
Taiwan
Query!
State/province [37]
0
0
Taipei
Query!
Country [38]
0
0
United Kingdom
Query!
State/province [38]
0
0
Greater London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this clinical research study is to learn whether Abatacept can treat and prevent lupus flares; specifically, in patients with active lupus flares in at least one of three organ systems: skin (discoid lesions); inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints (arthritis). All participants will receive prednisone or prednisone-equivalent treatment in combination with study medication. The safety of this treatment will also be studied.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00119678
Query!
Trial related presentations / publications
Hu Y, Carman JA, Holloway D, Kansal S, Fan L, Goldstine C, Lee D, Somerville JE, Latek R, Townsend R, Johnsen A, Connolly S, Bandyopadhyay S, Shadick N, Weinblatt ME, Furie R, Nadler SG. Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Arthritis Rheumatol. 2018 Aug;70(8):1331-1342. doi: 10.1002/art.40476. Epub 2018 Jul 12. Bandyopadhyay S, Connolly SE, Jabado O, Ye J, Kelly S, Maldonado MA, Westhovens R, Nash P, Merrill JT, Townsend RM. Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Sci Med. 2017 Jul 28;4(1):e000206. doi: 10.1136/lupus-2017-000206. eCollection 2017. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct;62(10):3077-87. doi: 10.1002/art.27601.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00119678
Download to PDF